IE65040B1 - Optimized fermentation processes for the preparation of foreign proteins in E coli - Google Patents
Optimized fermentation processes for the preparation of foreign proteins in E coliInfo
- Publication number
- IE65040B1 IE65040B1 IE278590A IE278590A IE65040B1 IE 65040 B1 IE65040 B1 IE 65040B1 IE 278590 A IE278590 A IE 278590A IE 278590 A IE278590 A IE 278590A IE 65040 B1 IE65040 B1 IE 65040B1
- Authority
- IE
- Ireland
- Prior art keywords
- lactose
- coli
- limitation
- addition
- iptg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention describes optimised fermentation processes for the production of foreign proteins in E.coli using the lac promoter or improved lac promoter (e.g. tac, trc). After the initial growth phase with glucose as carbon source, product formation is induced (1) by IPTG with glucose limitation or (2) by lactose with lactose limitation or (3) by IPTG and lactose with lactose limitation. The limitation of glucose or lactose is such that the partial pressure of oxygen remains above 10%.
Description
The invention describes optimized fermentation processes for the preparation of foreign proteins in E.coli using the lac promoter or improved lac promoter (for example tac, trc) . After the initial growth phase with glucose as carbon source, induction of product formation is effected (1) via IPTG with glucose limitation or (2) via lactose or (3) via IPTG and lactose with lactose limitation. The limitation of glucose or lactose is such that the oxygen partial pressure remains above 10%.
The preparation of commercial quantities of many different recombinant proteins in E.coli is well known in principle. The expression of these proteins becomes possible by cloning the coding cDNA into a multicopy plasmid with the appropriate sequences.
Expression experiments on this are normally carried out in shaken flasks. The yields of recombinant proteins in this case are usually 50 - 100 mg/1 when cultures in shaken flasks with volumes less than 100 ml are employed.
Although it is possible with these techniques successfully to prepare recombinant proteins, there is a need for techniques with which the protein concentrations and the preparable quantities are distinctly increased. One approach which meets these requirements is the develop30 ment of a fermentation process. The object of the invention is consequently the optimization of fermentation processes for the expression of foreign proteins in E.coli.
Several such processes with which the said requirements have at least partially been met have been described in the literature. The use of the lac promoter in these cases has meant that usually fusion proteins with an Nterminal ^-galactosidase portion (0-Gal) have been prepared. The yields in the fermentation are normally between 0.1 and 2.0 g of fusion protein per liter. When the fused 0-Gal portion is taken into account, the actual product concentration often decreases to 30% of the said value. Furthermore, elaborate purification processes are required to remove the 0-Gal portion from the product.
The present invention describes, inter alia, the expression of a mature product, i.e. the expression of a product without a fusion portion which would subsequently have to be eliminated again. Purification of the product is made relatively straightforward by such processes. However, in fermentation both the specific and the volumetric yields of the products are normally considerably lower. This is particularly true when the product of the process is prepared in soluble and biologically completely active form. In contrast to the formation of protein which is inactive and stored as inclusion bodies, the soluble and biologically active product may intervene in the metabolism of the cells and cause drastic disturbances in the organism (E.coli) and may be degraded considerably more easily by E.coli proteases. Despite these problems, it has been possible in the processes to date, in which glucose was employed as carbon source and isopropyl thiogalactoside (IPTG) was used for induction, to obtain yields of 200 mg/1 of biologically completely active product.
In order to optimize the fermentation, the invention entailed improvements in the growth behavior and product formation. Since the product is formed within the cells, the specific product concentration (quantity of product per cell) and the cell count are important. The product of the two factors is the volumetric productivity of the process in grams per liter (g/1).
High cell density fermentations have frequently been described in the literature for recombinant E.coli strains. Cell densities up to 30 g of dry matter (DM) per liter (1) are usually stated in this connection. It has been possible, by a combination of several measures which are known in principle, to develop a process in which the recombinant E.coli K12 strain was fermented up to cell densities of 50 g of DM/1, corresponding to 150 A^. The essential point here is that oxygen-enrichment of the inlet air is not a condition of the process which is described hereinafter. This has a beneficial effect on the economics of the process because pure oxygen as substrate results in high costs and, additionally, it is possible to dispense with explosion-protection measures.
An important factor for a process with a high volumetric product yield is optimal induction of the promoter. Induction with IPTG, which is carried out with the abovementioned low cell densities, is described many times in the literature.
It has been found that an improvement in the volumetric yields by a factor of 5, from 0.2 g/1 to 1.0 g/1, is achieved after induction by IPTG (1 mM to 10 mM, preferably 5 mM) and limitation of glucose as substrate in such a way that the oxygen partial pressure is greater than or equal to 10%.
A second embodiment of the invention comprises induction of product formation in the case of growth with lactose as carbon source and simultaneously natural inducer. The oxygen partial pressure was likewise maintained at greater than or equal to 10% as above by controlling the lactose addition. Induction by lactose is regarded in the literature as suboptimal because this procedure is alleged to be less efficient than IPTG induction. To date, no efficient fermentation processes in which lactose was employed as inducer have been described. The experimental approach according to the invention is based on the consideration that a higher final concentration of product can be achieved by a weaker induction and thus slower product formation, because the slower product formation has a less disturbing effect on the intrinsic metabolism of E.coli. This approach has been confirmed in appropriate experiments in which product concentrations of 2 g/1 (+/-10%) were achieved, corresponding to a doubling relative to above. The process differs from the previous one induced by IPTG in that glucose was replaced by lactose in the linear phase of growth. In the range of high metabolic activities at the end of the fermentation, when addition of lactose was also limited in order to maintain the partial pressure of oxygen above 10%, it was possible in a third variant of the process to assist the induction by lactose additionally by IPTG additions. This additional IPTG induction is necessary only when the power input of the specific chosen fermentation apparatus is inadequate to supply the culture with oxygen. Since an increased plasmid loss is observed in the second process described, on scale-up there is a crossing point as the fermentation volumes increase, after which first the second and then the first process is more economic, because a slightly increased plasmid loss is observed on induction with lactose.
The fermentation is terminated at the time when the product concentration is at a maximum. Processes known to those skilled in the art are used to concentrate (for example in a separator) and disrupt (for example in a high-pressure homogenizer) the biomass. After sedimentation of the cell fragments, most of the product is located in the clarified supernatant.
Accordingly, the invention relates to optimized fermentation processes for the expression of foreign genes in E.coli under the control of the lac promoter or optimized lac promoter, with induction being effected at the end of the exponential phase of growth by (1) IPTG with simultaneous substrate-limited glucose addition, and the oxygen partial pressure is maintained above 10% by the limitation of the glucose addition, (2) or by lactose as carbon source and simultaneously natural inducer, with the oxygen partial pressure being maintained above 10% by the limitation of the lactose addition, (3) or by lactose as carbon source and simultaneously natural inducer and, in addition, IPTG, with the oxygen partial pressure being maintained above 10% by the limitation of the lactose addition.
In preferred variants of the process, in each case the oxygen partial pressure is increased by one or more of the following measures: (a) Fermentation under superatmospheric pressure, preferably up to 2 bar (b) Controlled following of the power input (increasing the stirrer speed) and of the aeration rate (up to 2 wm) (c) Reducing the temperature from 37°C to as far as 30°C in order, via an improved Henry coefficient and reduced metabolic activity, to increase the oxygen transfer rate and reduce the oxygen uptake rate (necessary on scale-up above 1,000 1 because the specific power input decreases with increasing batch size (= container)).
It is common to all the variants of the process that the addition of sugar substrate as carbon source is controlled to maximum values of 5 - 10 g/1 and the pH is controlled by addition of NHAOH and H3PO4 in the range from pH 6.7 to pH 7.3 throughout the fermentation period.
The processes described above are preferably employed for the genetically engineered preparation of the proteins PP4 and PP4-x, which belong to the lipocortins, (Grundmann et al., Proc. Natl. Acad. Sci. 85, (1985) 3708-3712) and the mutants and variants thereof.
The invention is further described in the examples and patent claims.
Example: The following example describes the fermentation of the E.coli K12 strain W3110 lac IQ (Brent and Ptashne (1981) Proc.Acad.Natl.Sci. USA 78, 4204-4208), this strain having been transformed with the plasmid pTrc99A-PP4 (Amann et al. (1988) Gene 69, 301-315) or pTrc99A-PP4-X (Grundmann et al. (1988) Behring Inst. Mitt. 82, 59-67).
Tab. 1 indicates a very suitable medium.
Tab. 1 Composition of an example of a growth medium; (data in g or mg per liter) Carbon source (sugar) as required Yeast extract 20 g NaH2PO4 x H20 1.2 g Na2HPO4 x 2 H20 8.5 g KC1 1.0 g MgSO4 x 7 H20 2.0 g Citric acid 0.25 g NH4C1 5.0 g Thiamine 5.0 mg H3BO3 2.0 mg (NH4) 6Mo7024x4 H20 0.8 mg CuSO4 x 5H20 0.16 mg KI 0.4 mg MnSO4 x 7 H20 2.02 mg ZnSO4 x 7 H20 1.6 mg Fermentation was carried out in a 10 1 Biostat E fermenter (manufacturer: Braun Melsungen) with a fermentation volume of 8 1.
During the fermentation no selection pressure was exerted on plasmid-containing cells, i.e. the fermentation was carried out without added antibiotics. The fermenter was inoculated with an overnight shaken-flask preculture. Glucose was employed as carbon source in the initial phase of growth, the glucose being metered in so as to form less than 0.1 M acetic acid in this phase. Increased acetate concentrations resulted in significantly lower product yields. After 10-15 hours in the initial phase of growth, cell concentrations of about 50 OD650 had been achieved, and induction of product formation was effected in three different alternative ways; (1) Metering-in of glucose continued after addition of 1-10 mM IPTG (preferably 5 mM IPTG) At the end of the initial phase of growth, the product formation was induced by adding 1-10 mM IPTG (preferably 5 mM IPTG) while continuing to meter in glucose as carbon source (substrate). In this case the rate of product formation showed a distinct dependence on the glucose concentration at the time. Glucose as actual substrate and IPTG as apparent substrate appear as competing substrates, with, according to the rules of diauxia, glucose partially or completely suppressing the activation of the lac operon. In this case yields of 1 g/1 PP4 or PP4-X were attained in the glucose-limited system (glucose concentration less than 0.1 g/1).
The glucose limitation was carried out by setting the pump or by means of on-line HPLC measurement. The growth rate of the cells was not decreased by induction in nonlimited systems, while the growth rate of the cells decreased as a function of the glucose concentration in limited systems as expected. Cell densities between 100 and 150 OD650 were reached, depending on the relevant growth rates. (2) Metering in of lactose continued At the end of the initial growth phase, the product formation was induced by replacing glucose by lactose as carbon source. Lactose is the physiological inducer of the lac operon, but it brings about less complete induction than IPTG. During the induction phase, the cells continued to grow to cell densities of 100 OD650. The product concentration reached values of 1.5 g/1. (3) Metering in of lactose continued, and additions of 1-10 mM IPTG (preferably 5 mM) At the end of the initial growth phase, the product formation was induced by replacing glucose by lactose as carbon source and additionally adding IPTG. In this case, strong induction is brought about by IPTG and, at the same time, the physiological substrate lactose is utilized. Accurate metering in of the carbon source is unnecessary in this case, in contrast to glucose + IPTG. An excess of up to 30 g/1 lactose has no adverse effect on productivity. During induction the cells likewise continue to grow up to cell densities of 100 OD650. The product concentration at the end of fermentation is 2.0 g/1.
The induction is carried out by one of the processes as a function of the particular fermentation batch size, because the plasmid stability decreases from (1) to (3).
The fermentation parameters chosen in the described experiments are summarized in Tab. 2.
Tab. 2: Fermentation parameters pH: 7.0(controlled by addition of H3PO4 and NHA0H) Aeration rate: Number of revolutions: Temperature: Gage pressure: Substrate concentration: 0.5 - 2.0 wm 1,500 rpm 37°C (to 30°C) to 2.0 bar Glucose controlled at less than 5.0 g/1, limited when dissolved oxygen decreases; lactose controlled in subsequent metering in (less than 30 g/1), limited when dissolved oxygen decreases.
Dissolved oxygen: greater than 10%
Claims (6)
1. A process for the expression of foreign genes in E.coli under the control of the lac promoter or i optimized lac promoter, wherein induction is. effected at the end of the exponential phase of v growth by a) IPTG with simultaneous substrate-limited glucose addition, and the oxygen partial pressure is maintained above 10% by the limitation of the glucose addition, or b) lactose as carbon source and simultaneously natural inducer, with the oxygen partial pressure being maintained above 10% by the limitation of the lactose addition, or c) lactose as carbon source and simultaneously natural inducer and, in addition, IPTG, with the oxygen partial pressure being maintained above 10% by the limitation of the lactose addition.
2. The process as claimed in claim 1, wherein at least one of the following constituents of the process is applied (a) fermentation under superatmospheric pressure, preferably up to 2 bar, (b) controlled following of the power input (increasing the stirrer speed) and of the aeration rate (up to 2 wm), (c) reducing the temperature from 37°C to as far as 30®C, (d) controlled addition of substrate as carbon source to maximum values of 5 to 10 g/1 Λ (e) controlling the pH to values between pH 6.7 to pH 7.3.
3. The process as claimed in claim 1, wherein E.coli strains containing cDNA of lipocortins are fermented. B
4. The process as claimed in claim 3, wherein the cDNA codes for PP4 , PP4-x or mutants and variants of PP4. • 5 A process as claimed in claim 1 for the expression of foreign genes in E. Coli, substantially as hereinbefore described
5. And exemplified.
6. An expressed foreign gene in E. Coli whenever obtained by a process claimed in a preceding claim.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3925550A DE3925550A1 (en) | 1989-08-02 | 1989-08-02 | OPTIMIZED FERMENTATION PROCEDURES FOR THE MANUFACTURE OF FOREIGN PROTEINS IN E.COLI |
Publications (2)
Publication Number | Publication Date |
---|---|
IE902785A1 IE902785A1 (en) | 1991-02-27 |
IE65040B1 true IE65040B1 (en) | 1995-10-04 |
Family
ID=6386347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE278590A IE65040B1 (en) | 1989-08-02 | 1990-08-01 | Optimized fermentation processes for the preparation of foreign proteins in E coli |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0411501B1 (en) |
JP (1) | JP2977241B2 (en) |
KR (3) | KR100190777B1 (en) |
AT (1) | ATE111528T1 (en) |
AU (1) | AU624982B2 (en) |
CA (1) | CA2022487C (en) |
DE (2) | DE3925550A1 (en) |
DK (1) | DK0411501T3 (en) |
ES (1) | ES2060876T3 (en) |
IE (1) | IE65040B1 (en) |
PT (1) | PT94876B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9215550D0 (en) * | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
AT397812B (en) * | 1992-12-18 | 1994-07-25 | Polymun Scient Gmbh | Process for the expression of genes under the control of the lac operator |
KR0151534B1 (en) * | 1995-10-30 | 1998-08-17 | 이종호 | Escherichiacoli for suppressing the production of organic acid |
KR101035043B1 (en) | 2002-07-01 | 2011-05-19 | 아르키온 라이프 사이언씨즈 엘엘씨 | Process and Materials for Production of Glucosamine and N-acetylglucosamine |
US9096874B2 (en) | 2009-07-28 | 2015-08-04 | Mitsui Chemicals, Inc. | Method for producing lactic acid under pressure that exceeds normal atmospheric pressure |
EP3147369A4 (en) | 2014-05-21 | 2018-02-07 | Ajinomoto Co., Inc. | Fibroin-like protein production method |
CN111850072B (en) * | 2019-04-29 | 2022-08-16 | 暨南大学 | Peptibody multi-epitope vaccine fermentation production process and application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152483B1 (en) * | 1983-08-22 | 1989-03-29 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing peptide |
CA1319630C (en) * | 1987-02-19 | 1993-06-29 | Satori Sone | Method of regulating expression of a foreign gene by controlling the sugar concentration in a medium and a process of producing a foreign gene product thereby |
-
1989
- 1989-08-02 DE DE3925550A patent/DE3925550A1/en active Granted
-
1990
- 1990-07-27 DE DE59007117T patent/DE59007117D1/en not_active Expired - Lifetime
- 1990-07-27 ES ES90114473T patent/ES2060876T3/en not_active Expired - Lifetime
- 1990-07-27 DK DK90114473.3T patent/DK0411501T3/en active
- 1990-07-27 AT AT90114473T patent/ATE111528T1/en not_active IP Right Cessation
- 1990-07-27 EP EP90114473A patent/EP0411501B1/en not_active Expired - Lifetime
- 1990-07-31 KR KR1019900011693A patent/KR100190777B1/en not_active IP Right Cessation
- 1990-08-01 AU AU60005/90A patent/AU624982B2/en not_active Expired
- 1990-08-01 PT PT94876A patent/PT94876B/en not_active IP Right Cessation
- 1990-08-01 IE IE278590A patent/IE65040B1/en not_active IP Right Cessation
- 1990-08-01 CA CA002022487A patent/CA2022487C/en not_active Expired - Lifetime
- 1990-08-01 JP JP2202616A patent/JP2977241B2/en not_active Expired - Lifetime
-
1998
- 1998-09-19 KR KR1019980038814A patent/KR100190778B1/en not_active IP Right Cessation
- 1998-09-19 KR KR1019980038815A patent/KR100190779B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2977241B2 (en) | 1999-11-15 |
DK0411501T3 (en) | 1995-01-16 |
EP0411501B1 (en) | 1994-09-14 |
ES2060876T3 (en) | 1994-12-01 |
IE902785A1 (en) | 1991-02-27 |
KR910004811A (en) | 1991-03-29 |
ATE111528T1 (en) | 1994-09-15 |
PT94876B (en) | 1997-04-30 |
AU6000590A (en) | 1991-02-07 |
DE3925550C2 (en) | 1991-08-08 |
DE3925550A1 (en) | 1991-02-07 |
KR100190777B1 (en) | 1999-06-01 |
CA2022487A1 (en) | 1991-02-03 |
KR100190779B1 (en) | 1999-06-01 |
KR100190778B1 (en) | 1999-06-01 |
CA2022487C (en) | 2001-12-11 |
EP0411501A1 (en) | 1991-02-06 |
JPH0376595A (en) | 1991-04-02 |
DE59007117D1 (en) | 1994-10-20 |
PT94876A (en) | 1991-04-18 |
AU624982B2 (en) | 1992-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140329277A1 (en) | Method for culturing cells in order to produce substances | |
MXPA03001487A (en) | Improved methods for growing mammalian cells in vitro. | |
WO1990003431A1 (en) | Mixed feed recombinant yeast fermentation | |
EP2534255B1 (en) | Method of reducing glycosylation of proteins, processes and proteins thereof | |
US6033875A (en) | Method of improved production of insulin-like growth factor | |
CA2022487C (en) | Optimized fermentation processes for the preparation of foreign proteins in e.coli | |
EP3277807B1 (en) | Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters | |
EP2611900B1 (en) | Alkaline feed | |
EP0592692B1 (en) | Fed batch process for protein secreting cells | |
Turner et al. | Optimization of pro‐urokinase secretion from recombinant Saccharomyces cerevisiae | |
US8691530B2 (en) | Process for obtaining aspart insulin using a Pichia pastoris yeast strain | |
US5866371A (en) | Process for using the yeast ADH II promoter system for the production of heterologous proteins in high yields | |
US6750045B2 (en) | Fermentation medium and method | |
KR100405944B1 (en) | Protein manufacturing method | |
JP3592330B2 (en) | A method for controlling metal phosphate precipitation in high cell density fermentation | |
US5104795A (en) | Shortened phosphoglycerate kinase promoter | |
CN113462648A (en) | Mammalian cell culture process for efficiently expressing recombinant cat interferon omega 2 mutant | |
Park et al. | Fed-batch fermentations of recombinant Escherichia coli to produce Bacillus macerans CGTase | |
EP0245479B1 (en) | Shortened phosphoglycerate kinase promoter | |
KR102040926B1 (en) | Cell culture method at low temperature applicable to mass production of protein | |
KR20040026508A (en) | A Method for Increasing Productivity of Exogeneous Protein in Bacteria | |
Bongers et al. | Enzymatic Semisynthesis of Growth Hormone-Releasing Factor and Potent Analogs | |
KR19990027554A (en) | Method for producing recombinant protein using recombinant yeast | |
AU2002319639A1 (en) | Fermentation medium and method | |
KR20090083787A (en) | Over expression e.coli vector and its use for producing human basic fibroblast growth factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |